Amgen Inc.
APELIN POLYPEPTIDES
Last updated:
Abstract:
The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
Status:
Application
Type:
Utility
Filling date:
28 Jan 2021
Issue date:
26 Aug 2021